Bioequivalence Study of Torrent Pharmaceuticals Ltd.'s Fluoxetine Tablet Under Fasting Conditions
An Open Label, Randomized, 2-Period, 2-Treatment,2-Sequence, Crossover, Single-Dose BE Study of Fluoxetine Tablets 20 mg [Torrent,India] Versus Sarafem 20 mg Tablet [ Warner Chilcott LLC, USA] in Healthy Subjects-Fasted Condition.
1 other identifier
interventional
26
0 countries
N/A
Brief Summary
Subjects to compare the single dose bioavailability of Torrent's Fluoxetine Tablets 20 mg and Sarafem® 20 mg Tablets of Warner Chilcott LLC, USA. Dosing periods of studies were separated by a washout period of 35 days.
Trial Health
Trial Health Score
Automated assessment based on enrollment pace, timeline, and geographic reach
participants targeted
Target at P25-P50 for phase_1
Started Nov 2013
Shorter than P25 for phase_1
Health score is calculated from publicly available data and should be used for screening purposes only.
Trial Relationships
Click on a node to explore related trials.
Study Timeline
Key milestones and dates
Study Start
First participant enrolled
November 1, 2013
CompletedPrimary Completion
Last participant's last visit for primary outcome
January 1, 2014
CompletedStudy Completion
Last participant's last visit for all outcomes
January 1, 2014
CompletedFirst Submitted
Initial submission to the registry
November 14, 2016
CompletedFirst Posted
Study publicly available on registry
November 16, 2016
CompletedNovember 16, 2016
November 1, 2016
2 months
November 14, 2016
November 14, 2016
Conditions
Outcome Measures
Primary Outcomes (2)
Cmax
pre-dose to 72 hours post-dose
AUC
pre-dose to 72 hours post-dose
Study Arms (2)
Test
EXPERIMENTALTorrent's Fluoxetine Tablets 20 mg
Reference
ACTIVE COMPARATORWarner Chilcott LLC's Sarafem® Tablet 20 mg
Interventions
Eligibility Criteria
You may qualify if:
- Sex: male
- Age: 18-45 years (inclusive both)
- Volunteer with BMI of 18.5-27 (inclusive both) kg/m2 with minimum of 50 kg weight.
- Healthy and willing to participate in the study.
- Volunteer willing to provide written informed consent.
- Non-smokers or smoker who smokes less than 10 cigarettes per day.
You may not qualify if:
- Inability to communicate or co-operate.
- Volunteers suffering from any chronic illness such as arthritis, asthma etc.
- History of pre-existing bleeding disorder.
- Clinically relevant abnormalities in the results of the laboratory screening evaluation.
- Clinically significant abnormal ECG or Chest X-ray.
- HIV, HCV, HBsAg positive volunteers.
- History of significant blood loss due to any reason, including blood donation in the past 3 months.
- Participation in any study within past 3 months,
- History of alcohol or drug abuse.
- History of consumption of prescribed medication since last 14days or OTC medication/ herbal remedies since last 7 days before beginning of the study. Positive to Breath alcohol test.
- Positive to breath alcohol test.
- Volunteer found to be positive for Opiate, tetra hydrocannabinol, amphetamine, barbiturates, benzodiazepines, Cocaine positive volunteers based on urine test.
- Systolic blood pressure less than 100 mmHg or more than 139 mmHg and diastolic blood pressure less than 60 mm Hg or more than 89 mm Hg.
- Pulse rate less than 60/minute or more than 100/minute.
- Oral temperature less than 95°F or more than 98.9°F.
- +5 more criteria
Contact the study team to confirm eligibility.
Sponsors & Collaborators
Study Design
- Study Type
- interventional
- Phase
- phase 1
- Allocation
- RANDOMIZED
- Masking
- NONE
- Purpose
- TREATMENT
- Intervention Model
- CROSSOVER
- Sponsor Type
- INDUSTRY
- Responsible Party
- SPONSOR
Study Record Dates
First Submitted
November 14, 2016
First Posted
November 16, 2016
Study Start
November 1, 2013
Primary Completion
January 1, 2014
Study Completion
January 1, 2014
Last Updated
November 16, 2016
Record last verified: 2016-11
Data Sharing
- IPD Sharing
- Will not share